ClinicalTrials.gg
RecruitingNCT07287410RE-MIDAUpdated Dec 17, 2025

Dementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms.

An observational study in Dementia and Mild Cognitive Impairment (MCI), sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Recruiting at 1 site in Italy. Open to participants aged 50 Years to 86 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
151
Ages
50 Years to 86 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Dementia with a site in Italy — 37 open to participants now, 44 under way, 7 of them phase 3. Dementia · Italy.

Planned enrollment
20th of 26
151 · median 283
Started
2025
with 8 others
Observational
26 of 92
13 open now
Primary completion
2026-12
later than 20 of 43 live
Registered
82nd of 92
by date
Lead sponsor
4 of 92
IRCCS Centro Neurolesi Bonino Pulejo

Among the 92 studies in Dementia with a site in Italy, this one is the 20th largest by planned enrollment of the 26 observational ones that give a count, is one of 9 that started in 2025, is one of 26 observational ones, reaches primary completion later than 20 of the 43 other live ones, and was the 82nd registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

37 of the 92 studies in Dementia with a site in Italy are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 50 Years to 86 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Dementia with a site in Italy, or all of them as a file.
02

Study summary

Dementia, in its various forms, is characterized by a generalized cognitive decline that can significantly compromise personal autonomy and quality of life. Mild Cognitive Impairment (MCI), although not classified as an overt form of dementia, represents a condition at evolutionary risk and is considered a crucial transitional stage for the early detection of cognitive decline. Understanding the impact of dementia and MCI from a multidimensional perspective is now essential to fully grasp the repercussions of these conditions on patients' daily lives. The present protocol aims to investigate key aspects related to these disorders, with the objective of exploring cognitive functioning, the degree of impairment in activities of daily living, and the presence of neuropsychiatric symptoms. Through an integrated and multidisciplinary approach, the study seeks to enhance clinical management and patient care, promoting more effective, targeted, and personalized interventions.

Read the detailed description

The present protocol aims to evaluate several fundamental aspects related to dementia and Mild Cognitive Impairment (MCI). Specifically, the objective is to investigate cognitive functioning, the degree of impairment in autonomy in activities of daily living, and the presence of neuropsychiatric and mood disorders. Through this integrated perspective, the study seeks to promote improvements in clinical management and patient care, fostering more effective and personalized interventions. The primary objective of the study is to assess the level of functional autonomy in individuals affected by dementia or Mild Cognitive Impairment (MCI), with particular attention to both basic and instrumental activities of daily living, using the ADL and IADL scales. In addition to the main goal, the study aims to analyze the presence and extent of emotional and neuropsychiatric symptoms and to evaluate their impact on the overall psychological well-being of patients, using standardized psychometric tools that will be described in detail in later sections.

The study has an observational, retrospective design. Data will be collected from the neuropsychological assessments of patients who have undergone at least three testing sessions, approximately 12 months apart, at the Neuropsychology Outpatient Clinic of the IRCCS Centro Neurolesi Bonino Pulejo.

The sample size estimation was conducted in relation to the primary objective-evaluating the level of functional autonomy impairment in patients diagnosed with dementia or MCI, measured using the ADL and IADL scales. It was hypothesized that a mean difference of at least 1 point on the IADL scale between the two groups (patients with dementia vs. patients with MCI) would be clinically significant, assuming a standard deviation of 1.5, based on literature and clinical practice data. The statistical power was calculated using the G*Power software (version 3.1), selecting a two-tailed independent-samples t-test. Assuming an effect size (d) of 0.5, a significance level (α) of 0.05, and a statistical power (1-β) of 80%, the calculation indicated that at least 64 participants per group (MCI and dementia) would be required, for a total of 128 participants. Considering a potential dropout or loss to follow-up rate of 15%, an overall recruitment target of approximately 151 patients has been set. Participants will be recruited from the Neuropsychology Outpatient Clinic of the IRCCS Centro Neurolesi Bonino Pulejo in Messina.

Participants will be included in the study if, based on the available clinical documentation, they meet the following criteria:

  • Age between 50 and 86 years;
  • Suspected or confirmed diagnosis of dementia or Mild Cognitive Impairment (MCI), referred to the Neuropsychology Clinic for an initial evaluation or clinical monitoring;
  • Absence of behavioral, psychiatric, or sensory disturbances severe enough to significantly compromise the performance of cognitive tests or the completion of questionnaires.

Participants will be excluded from the study if, based on clinical record review, they meet any of the following conditions:

  • Presence of neurological disorders other than dementia or MCI, such as recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, or other atypical neurodegenerative diseases;
  • Unstable major psychiatric comorbidities at the time of assessment (e.g., schizophrenia, bipolar disorder in the active phase, untreated severe depression);
  • Severe uncorrected sensory deficits (visual or auditory) that compromise the validity of cognitive and functional assessments;
  • Use of medications with a significant cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of assessment;
  • Presence of terminal medical or oncological conditions, or other diseases that have significantly interfered with the assessment procedures.

The study involves retrospective collection of clinical and functional data from patients diagnosed with dementia or Mild Cognitive Impairment (MCI). Data from standardized tests will be extracted and analyzed from the medical records and databases available at the Neuropsychology Outpatient Clinic of the IRCCS Centro Neurolesi Bonino Pulejo in Messina, without any direct interventions involving the patients. Data will be entered into a secure database accessible only to study collaborators via personal credentials.

The following data will be collected:

  • Information necessary for retrospective verification of inclusion and exclusion criteria;
  • Demographic and clinical history data, including information on disease history and comorbidities;
  • Results from psychological, neuropsychological, and clinical tests administered during visits, including:

    • Mini-Mental State Examination (MMSE)
    • Montreal Cognitive Assessment (MoCA)
    • Milan Overall Dementia Assessment (MODA)
    • Activities of Daily Living / Instrumental Activities of Daily Living (ADL/IADL)
    • Beck Depression Inventory (BDI)
    • Beck Anxiety Inventory (BAI)
    • Geriatric Depression Scale (GDS)
    • Frontal Assessment Battery (FAB)
    • Hamilton Depression Rating Scale (HDR-S)
    • Hamilton Rating Scale for Anxiety (HRSA)
    • Clock Drawing Test (CDT)
    • Neuropsychiatric Inventory (NPI) This retrospective design allows for an in-depth analysis of disease progression and serves as a useful tool for the early identification of potential predictive factors of deterioration. The results are expected to have relevant implications for clinical management, intervention planning, and the personalization of patient care pathways.
03

Conditions studied

  • Dementia
  • Mild Cognitive Impairment (MCI)

Keywords

  • Dementia
  • Mild Cognitive Impairment
  • neuropsychological
  • Activities of Daily Living
  • Neuropsychiatric symptoms
04

Who can participate

Ages eligible
50 Years to 86 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

151

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 50 and 86 years.
  • Suspected or confirmed diagnosis of dementia or mild cognitive impairment (MCI).
  • Referral to the neuropsychology clinic for initial assessment or clinical monitoring.
  • Absence of behavioral, psychiatric, or sensory disorders severe enough to significantly impair cognitive testing or completion of questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Presence of neurological disorders other than dementia or MCI (e.g., recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, atypical neurodegenerative diseases).
  • Unstable major psychiatric comorbidities at the time of assessment (e.g., schizophrenia, bipolar disorder in active phase, untreated severe depression).
  • Uncorrected severe sensory deficits (visual or auditory) affecting the validity of cognitive or functional assessments.
  • Use of medications with significant cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of evaluation.
  • Presence of terminal medical or oncological conditions or other illnesses significantly interfering with the assessment procedures.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
151 participants (estimated)
Patient registry
No

Interventions

  • Othernone - observational study

    none - observational study

06

What researchers measure

Primary outcomes

  1. Dementia or Mild Cognitive Impairment (MCI) with ADL

    The primary outcome variable considered for calculation is the score of the Activities of Daily Living (ADL) scale, used as the main index of functional autonomy in subjects with dementia or mild cognitive impairment (MCI).

    Time frame: 12 MONTHS

Secondary outcomes

  1. Functional autonomy in instrumental activities measured with the Instrumental Activities of Daily Living (IADL) scale

    Assessment of functional autonomy in instrumental activities of daily living in subjects with dementia or mild cognitive impairment (MCI) using the Instrumental Activities of Daily Living (IADL) scale.

    Time frame: 12 MONTHS

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cappadona I, Corallo F, Pagano M, Cardile D, Bonanno L, Massimino S, De Luca R, Alagna A, Parisi L, Di Prima F, Marra A, Calabro RS, Anselmo A. Evaluation of functional autonomy and neuropsychiatric symptoms in dementia and Mild Cognitive Impairment: a retrospective observational protocol. Neurodegener Dis Manag. 2026 May 20:1-9. doi: 10.1080/17582024.2026.2676827. Online ahead of print. PubMed 42157749 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 17, 2025
StartEst.
Dec 2025
Primary completionEst.
Dec 20, 2026
CompletionEst.
Dec 20, 2026
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07287410
Lead sponsor
IRCCS Centro Neurolesi Bonino Pulejo
Responsible party
Francesco Corallo (Psychological manager, IRCCS Centro Neurolesi Bonino Pulejo) — Principal investigator
First posted
Dec 17, 2025
Start date
Dec 2025 (estimated)
Primary completion
Dec 20, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Dec 17, 2025

Study contacts

Francesco Corallo
Contact
francesco.corallo@irccsme.it
09060128335

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion